Search research articles
Contact Us
Filters
Showing results (181-190 of 265) with videos related to
Page
of 27
Sort By:
Journal of Personalized Medicine
|
March 27, 2026
Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors
Ilaria Poli, Gaia Rachele Oliva, Ginevra Mongelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2005
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide
Paola Papaldo, Massimo Lopez, Paolo Marolla, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 8, 2018
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)
Fausto Roila, Guglielmo Fumi, Benedetta Ruggeri, et al.
The Oncologist
|
July 1, 2025
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)
Carmine De Angelis, Martina Pagliuca, Emanuela Magnolfi, et al.
NPJ Breast Cancer
|
December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
Linda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.
Plos One
|
May 26, 2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
Stefania Gori, Alessandro Inno, Valentina Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Xavier Pivot, Alexey Manikhas, Bogdan Żurawski, et al.
Cancers
|
May 13, 2023
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting
Antonio Franco, Alba Di Leone, Alessandra Fabi, et al.
Current Oncology (Toronto, Ont.)
|
October 27, 2022
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer
Luisa Carbognin, Cristina Accetta, Danilo Di Giorgio, et al.
Journal of Neuro-Oncology
|
October 2, 2015
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)
Giuseppe Lombardi, Andrea Pace, Francesco Pasqualetti, et al.
Page
of 27
Search research articles
Search
Showing results (181-190 of 265) with videos related to
Sort By:
Page
of 27
Journal of Personalized Medicine
|
March 27, 2026
Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors
Ilaria Poli, Gaia Rachele Oliva, Ginevra Mongelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2005
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide
Paola Papaldo, Massimo Lopez, Paolo Marolla, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 8, 2018
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)
Fausto Roila, Guglielmo Fumi, Benedetta Ruggeri, et al.
The Oncologist
|
July 1, 2025
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)
Carmine De Angelis, Martina Pagliuca, Emanuela Magnolfi, et al.
NPJ Breast Cancer
|
December 18, 2024
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
Linda Cucciniello, Eva Blondeaux, Claudia Bighin, et al.
Plos One
|
May 26, 2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
Stefania Gori, Alessandro Inno, Valentina Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Xavier Pivot, Alexey Manikhas, Bogdan Żurawski, et al.
Cancers
|
May 13, 2023
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting
Antonio Franco, Alba Di Leone, Alessandra Fabi, et al.
Current Oncology (Toronto, Ont.)
|
October 27, 2022
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer
Luisa Carbognin, Cristina Accetta, Danilo Di Giorgio, et al.
Journal of Neuro-Oncology
|
October 2, 2015
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)
Giuseppe Lombardi, Andrea Pace, Francesco Pasqualetti, et al.
Page
of 27